m+Medelevator.RU
← Поиск публикаций
EMBO molecular medicine · 2014

Molecular pathogenesis of spondylocheirodysplastic Ehlers-Danlos syndrome caused by mutant ZIP13 proteins.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Bin Bum-Ho, Hojyo Shintaro, Hosaka Toshiaki, Bhin Jinhyuk, Kano Hiroki, Miyai Tomohiro, Ikeda Mariko, Kimura-Someya Tomomi, Shirouzu Mikako, Cho Eun-Gyung, Fukue Kazuhisa, Kambe Taiho, Ohashi Wakana, Kim Kyu-Han, Seo Juyeon, Choi Dong-Hwa, Nam Yeon-Ju, Hwang Daehee, Fukunaka Ayako, Fujitani Yoshio, Yokoyama Shigeyuki, Superti-Furga Andrea, Ikegawa Shiro, Lee Tae Ryong, Fukada Toshiyuki

Аннотация

The zinc transporter protein ZIP13 plays critical roles in bone, tooth, and connective tissue development, and its dysfunction is responsible for the spondylocheirodysplastic form of Ehlers-Danlos syndrome (SCD-EDS, OMIM 612350). Here, we report the molecular pathogenic mechanism of SCD-EDS caused by two different mutant ZIP13 proteins found in human patients: ZIP13(G64D), in which Gly at amino acid position 64 is replaced by Asp, and ZIP13(ΔFLA), which contains a deletion of Phe-Leu-Ala. We demonstrated that both the ZIP13(G64D) and ZIP13(ΔFLA) protein levels are decreased by degradation via the valosin-containing protein (VCP)-linked ubiquitin proteasome pathway. The inhibition of degradation pathways rescued the protein expression levels, resulting in improved intracellular Zn homeostasis. Our findings uncover the pathogenic mechanisms elicited by mutant ZIP13 proteins. Further elucidation of these degradation processes may lead to novel therapeutic targets for SCD-EDS.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты